Document:

Exhibit 10.23

 

CONSULTING AGREEMENT

 

Effective Date: January 1, 2012

 

Name and Address of Consultant:

 

E. Premkumar Reddy, Ph.D. (“Consultant”)

Mount Sinai School of Medicine

Department of Oncological Sciences

One Gustave L. Levy Place

New York, NY  10029

 

Federal Tax ID# or SSN#:

 

Name and Address of Onconova Contact:

Ramesh Kumar, Ph.D., President

Onconova Therapeutics, Inc.

375 Pheasant Run

Newtown, PA 18940

 

Terms and Conditions of Consulting Service

 

Onconova and Consultant agree:

 

1.                                      Scope of Work

 

Consultant will perform consulting and/or advisory services (the “Services”) as it relates to Onconova’s existing proprietary products and/or those already in planning and development prior to Consultant’s employment with Mount Sinai School of Medicine (MSSM) (collectively, the “Field”) for Onconova (“Onconova”) as described in greater detail in Schedule 1.  All services performed under this Agreement shall be in the Field.  Therefore all references herein (and in any attached schedule) to “Services” shall be understood as references to Services in the Field.  The attached schedules are hereby incorporated into and made fully a part of this Agreement.  Consultant is entering into this Agreement in Consultant’s individual capacity and not as an employee or agent of MSSM and confirms that Consultant’s performance of the Services in the Field under and during the Term of this Agreement shall be separate and distinct from Consultant’s job responsibilities as an employee of MSSM.

 

Consultant shall not perform any services for Onconova that would encroach on (i) Consultant’s job responsibilities as an employee of Mount Sinai or (ii) any non-publicly available, confidential, or proprietary information related to processes or clinical trials performed at Mount Sinai.  In performing the Services,

 

 

Consultant shall not function as an investigator on any research project and shall not perform any of the Services on Mount Sinai School of Medicine (“MSSM”) premises (with the exception of de minimis use of Consultant’s MSSM office, office computer, and school library).  Any photograph, videotape, reproduction, likeness or image of Consultant shall not be used by Onconova, its affiliates, subsidiaries or successors for recruiting, publicity, marketing, company/product endorsement or promotional purposes.  Any presentation Consultant provides in Consultant’s performance of the Services shall be of Consultant’s own creation; Consultant shall control the content of such presentation, and such presentation shall become the property of Onconova subject to the terms of Paragraph 7 of this Agreement.

 

2.                                      Compensation

 

Onconova will pay Consultant a consulting fee in the amount and on the terms specified in attached Schedule 1.

 

3.                                      Manner of Performance

 

Consultant will perform no Services on MSSM premises.  Consultant represents that Consultant’s performance of the Services in the Field under and during the Term of this Agreement shall not involve (i) the use of any facilities, space, materials or other resources of MSSM, including resources provided by outside sources, except de minimis use of Consultant’s MSSM office, office computer, and school library, or (ii) the use of financial support from MSSM, including funding from any outside source awarded to or administered by MSSM, or (iii) the use of any intellectual property developed within an area of research that Consultant has conducted or will conduct under a research project sponsored by MSSM or a third party, each of (i), (ii) and (iii) during the Term of this Agreement.  Consultant represents that Consultant has the requisite expertise, ability, and legal right to render the Services and will perform the Services in an efficient manner.  Consultant will abide by all laws, rules, and regulations that apply to the performance of the Services, including applicable requirements regarding equal employment opportunity and related rules.

 

4.                                      Confidentiality

 

Consultant hereby acknowledges that, in Consultant’s performance of the Services in the Field under and during the Term of this Agreement, Consultant may be provided with confidential and proprietary Onconova information (“Confidential Information”) and therefore, Consultant hereby confirms that all such Confidential Information will be kept confidential by Consultant, except to the extent required for performance of the Services in the Field.  “Developments” as defined below, shall also be considered Confidential Information.  Consultant shall not publish regarding the Services in the Field performed under and during

 

2

 

the Term of this Agreement without first providing Onconova with the opportunity to review and offer reasonable objection to the contemplated publication.  The confidentiality obligations and use restrictions of this Agreement regarding Confidential Information shall apply during the Term of this Agreement and for five (5) years after its termination or expiration.  Within fifteen (15) days of the termination or expiration of this Agreement, Consultant will return to Onconova all Confidential Information, including all copies thereof.

 

The confidentiality obligations and use restrictions regarding Confidential Information shall not apply to information that: (a) becomes part of the public domain without the fault of Consultant; (b) is rightfully obtained by Consultant from a third party with the right to transfer such information without imposing an obligation of confidentiality; (c) is independently developed by Consultant without use of Onconova’s Confidential Information, as evidenced by written record; or (d) was lawfully in Consultant’s possession at the time of disclosure to Consultant by Onconova, without restriction on disclosure, as evidenced by written record.  In addition, Consultant may disclose Confidential Information as required by law, court order, or other governmental authority with jurisdiction, provided that Consultant promptly notifies Onconova in writing of such requirement and complies, at Onconova’s written request and expense, with Onconova’s lawful efforts to prevent or limit the scope of such required disclosure.

 

5.                                      Notwithstanding the foregoing or anything else in this Agreement, Onconova acknowledges that Consultant is a full-time employee of Mount Sinai School of Medicine (“MSSM”) and agrees that, in the event the terms and conditions of this Agreement are in conflict with the terms and conditions of Consultant’s employment by MSSM, including the terms of any grants or contracts administered by MSSM for which Consultant performs services, the latter shall prevail.  Consultant represents that, as of the date of his/her execution of this Agreement, to the best of Consultant’s knowledge there are no such conflicts, and if any arise during the Term of this Agreement, Consultant shall promptly inform Onconova and Onconova shall have the right in such event immediately to terminate this Agreement.

 

6.                                      Independent Contractor

 

Consultant is an independent contractor, not an employee or agent of Onconova.  Nothing in this Agreement shall render Consultant, or any of his/her agents or employees, an employee or agent of Onconova, nor authorize or empower Consultant or his/her agents or employees to speak for, represent, or obligate Onconova in any way.  Onconova recognizes that Consultant retains all the rights and privileges of an employer, including but not limited to the right to hire, direct, discipline, compensate, and terminate its employees assigned to the Onconova

 

3

 

account.  Consultant assumes any and all liabilities regarding Section 1706 and Section 414(n) of the Internal Revenue Code of 1986.  Consultant is entering into this Agreement in Consultant’s individual capacity and not as an employee or agent of MSSM and confirms that Consultant’s performance of the Services in the Field under and during the Term of this Agreement shall be separate and distinct from Consultant’s job responsibilities as an employee of MSSM.

 

7.                                      Ownership of Developments

 

All written materials and other works that may be subject to copyright and all patentable and unpatentable inventions, and discoveries (including but not limited to any computer software) that are made, conceived, or written by Consultant in Consultant’s performance of the Services in the Field under and during the Term of this Agreement (“Developments”) shall be Onconova’s property.  Consultant agrees to hold all Developments confidential in accordance with paragraph 4 of this Agreement.

 

Notwithstanding the foregoing, Onconova shall not acquire any rights by reason of this Agreement in any publication, invention, discovery, improvement or other intellectual property, whether or not publishable, patentable or copyrightable, or any other results of research developed as a result of a program of research financed, in whole or in part, by funds under the control of MSSM.  Any intellectual property right regarding works, inventions and/or discoveries made under any agreement between Onconova and MSSM shall be governed by such agreement.

 

8.                                      Disclosure and Transfer of Developments

 

Consultant will disclose promptly to Onconova each Development and, upon Onconova’s request and at Onconova’s expense, Consultant will assist Onconova, or anyone it designates, in filing a patent or copyright application in any country in the world covering such Development.  Each Development that is a copyrightable work, to the extent permitted by law, will be considered a work made for hire and the authorship and copyright in the work shall be in Onconova’s name.  During the Term, Consultant will execute all papers and do all things, which may be necessary or advisable, in the opinion of Onconova, to process such applications and to vest in Onconova, or its designee, all the right, title, and interest in and to Developments.  If for any reason Consultant is unable to effectuate a full assignment of any Development, Consultant will transfer to Onconova, or its designee, its transferable rights, whether they be exclusive or nonexclusive, or as a joint inventor or partial owner of the Development.

 

4

 

9.                                      Disclosures to Onconova

 

If during the term of this Agreement, Consultant discloses any copyrightable works, inventions, or discoveries, to Onconova that were conceived or written prior to this Agreement, or which are not made or conceived in performance of the Services in the Field under and during the Term of this Agreement, Onconova will have no liability to Consultant because of its use of such works, inventions, or discoveries, except liability for infringement of any valid copyright or patent now or hereafter issued thereon.

 

10.                               Term

 

The term of this Agreement shall be from the Effective Date through the termination date specified in Schedule 1 unless earlier terminated in accordance with paragraph 11 (the “Term”).  This agreement may be renewed through written amendment agreed to by the parties, including review and approval by Consultant’s employer MSSM for compliance with MSSM’s policies.

 

11.                               Termination

 

Onconova may terminate this Agreement effective the day of notice by giving Consultant written notice of such termination if: (a) Consultant breaches any of his/her material obligations under paragraphs 4, 8, or 9 of this Agreement; or (b) fails to provide the standard of performance of Services that substantially meets Onconova’s reasonable expectations; or (c) fails at any time, given reasonable notice, to provide the contracted Services defined in the Schedules attached hereto.  If Onconova determines that it no longer requires the services of Consultant, it may terminate this Agreement by giving Consultant thirty (30) days’ written notice.  Likewise, Consultant may terminate this Agreement by giving Onconova thirty (30) days’ written notice.  Consultant will have the right to terminate this Agreement immediately if Onconova fails to provide payment for Services rendered within a period of thirty (30) days following submission of an invoice.

 

12.                               MSSM Name Use

 

Except for accurately describing Consultant’s affiliation with MSSM, neither party shall use MSSM’s name in a manner that would identify MSSM with any product or any commercial or Other activity that would imply endorsement or support thereof by MSSM.

 

13.                               General

 

Neither party may assign this Agreement.  This Agreement supersedes all prior agreements between the parties respecting the Services in the Field.  This

 

5

 

Agreement may not be changed or terminated orally by or on behalf of either party.  In the event either party breaches this Agreement, the other party will have the right to terminate this Agreement.  In the event of actual or threatened breach of any of the terms of paragraphs 4, 8, or 9, Onconova will have the right to seek specific performance and injunctive relief.  The rights granted by this paragraph are in addition to all other remedies and rights available at law or in equity.  This Agreement shall be construed according to the laws of the Commonwealth of Pennsylvania for contracts made within that state.

 

Any notice required or permitted to be given under this Agreement will be sufficient if in writing and if delivered personally, or sent by certified or registered mail as follows (or to such address as will be set forth in a notice given in the same manner):

 

If to Consultant:

 

E. Premkumar Reddy, Ph.D.
 Mount Sinai School of Medicine
 Department of Oncological Sciences
 One Gustave L. Levy Place
 New York, NY 10029

 

If to Onconova:

 

Ramesh Kumar, Ph.D., President
 Onconova Therapeutics, Inc.
 375 Pheasant Run
 Newtown, PA 18940

 

Accepted and Agreed by:

 

Consultant:

 

 

	
/s/ E. Premkumar Reddy
    	
 
    	
July 25, 2012
    
	
E. Premkumar Reddy, Ph.D.
    	
 
    	
Date
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Onconova   Therapeutics, Inc.:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/   Ramesh Kumar
    	
 
    	
July 27,   2012
    
	
Ramesh   Kumar, Ph.D.
    	
 
    	
Date
    

 

6

 

Schedule 1

 

Description of Services in the Field:

 

Consultant’s consulting and/or advisory services shall include:

 

Guidance and opinion on Temple University’s Intellectual Property that has been licensed for commercialization through Onconova (the “Patents”), including:

 

·                                          Explanation of development of original compounds, as it relates to Patents

·                                          Synthesis of compounds, as it relates to Patents

·                                          Feasibility aspects of Patents

·                                          Commercialization aspects of Patents

 

Compensation

 

Consultancy will be for a maximum of 25 full days (or 200 hours) at the annual rate of $165,000.00.  Payment will be made quarterly.

 

Term

 

This Agreement will be in effect until 12/31/2012, renewable.

 

 

CONSULTANT AGREEMENT RENEWAL

 

February 27, 2013

 

E. Premkumar Reddy, Ph.D.

Professor, Department of Oncological Sciences

and Department of Structural and Chemical Biology

Director, Experimental Cancer Therapeutics

Mount Sinai School of Medicine

1425 Madison Avenue

New York, NY 10029

 

Dear Dr. Reddy:

 

This letter refers to your Consulting Agreement with Onconova Therapeutics Inc.  We wish to renew this agreement thru December 31, 2013.  If in agreement, please sign and return a copy of this letter via email: lisa@onconova.us or via fax: 215-529-6580.

 

Best regards,

 

	
/s/   Ramesh Kumar
    	
 
    
	
 
    	
 
    
	
Ramesh   Kumar, Ph.D.
    	
 
    
	
President   and CEO
    	
 
    

 

I agree to renew my consulting agreement thru December 31, 2013.

 

 

	
/s/   E. Premkumar Reddy
    	
 
    
	
E.   Premkumar Reddy, Ph.D.Lithium Exploration Group, Inc.: Exhibit 10.1 - Filed by newsfilecorp.com

	LITHIUM EXPLORATION GROUP INC. 
	3200 N. Hayden Road, Suite 235, 
	Scottsdale, Arizona 858251

	June 11, 2013 
	  
	Blue Tap Resources 
	3031 31 St. SW 
	Calgary, AB T3E 3A2 
	  
	Attention: Mr. Vincent Murphy, President
  

Re: Letter of Intent for the acquisition of Blue Tap
Recourses (“Blue Tap”) by Lithium Exploration Group,
Inc. (“LEXG”)

This letter confirms our mutual intention to enter into a
definitive share exchange agreement whereby LEXG will acquire not less than 80%
of the issued and outstanding securities of Blue Tap (the “Transaction”).
This letter is intended to create legally binding obligations on the parties and
will serve as the basis for the negotiations and preparation of a definitive
agreement among LEXG, Blue Tap, and the selling shareholders of Blue Tap (the
“Selling Shareholders”) leading to the completion of the Transaction.

1. The Transaction

Structure: The Transaction shall be effected by way of a
cash investment whereby LEXG will purchase not less than 80%. This purchase will
be undertaken initially by the making available of $150,000.00 CDN to be used by
Blue Tap, under LEXG fund control and supervision, for the purposes of carrying
out the required step to obtain approval for, and the return of, the facility to
active operation as a water disposal facility. LEXG will agree to make available
an additional $150,000.00 CDN to be applied to toward liability security
deposits required under the Alberta Regulatory Framework at the time which it is
required. It is to be understood that funds put on deposit for liability
requirements will, upon those funds being released by the Alberta Energy
Regulator be made available only for the purposes of furthering facility
development. The first two payments of $150,000 to Blue Tap for the aggregate of
$300,000 shall be considered a bridge loan, with such terms and repayment
provisions to be specified in the Transaction Agreement, until and unless the
following conditions are satisfied for the funding of the additional $150,000.
Provided that initial efforts to return the facility to revenue producing status
are successful and efforts toward obtaining approvals to move the facility to
Class 1A waste designation are ongoing with progress satisfactory to LEXG, an
additional $150,000.00 CDN will be made available for purposes of continued
facility development.

Upon funding of $450,000.00 CDN under the preceding terms, LEXG
shall be considered to have purchased a 51% equity interest in Blue Tap. At that
point LEXG has an option to purchase an additional 9% of Blue Tap for
$100,000.00 CDN (in shares and/or cash) and shall be considered to have
purchased 60% of the fully diluted equity interests of Blue Tap. Any additional
capital expenditures will be handled on a working interest basis but the selling
shareholders of Blue Tap cannot be diluted to less than 30% equity in the
entity. The selling shareholders will also receive a GORR not less than 3% but
not to exceed $150,000/yr with details to be finalized and structured in the
Transaction Agreement.

Assets shall be as specified but not limited to those outlined
in attached Schedule A.

1.1 Terms and conditions: The definitive agreement under
which the parties will agree to carry out the Transaction (the “Transaction
Agreement”) will contain provisions that are customary for a transaction of
this nature, and will include (but not be limited to) representation and
warranties of each LEXG, Blue Tap, and the Selling Shareholders of Blue Tap, (as
applicable), including LEXG’s status as a reporting issuer with the U.S.
Securities and Exchange Commission Exchange (the “SEC”), and all representations
and warranties required to ensure compliance with applicable United States and
Canadian securities law. The conditions precedent to closing of the Transaction
in favor of both LEXG and Blue Tap will include the following:

	 	(a) 	
      receipt of all required regulatory approvals to the
      carrying out of the Transaction;

	 	 	 
	 	(b) 	
      approvals of the boards of directors of Blue Tap and LEXG
      and shareholders of Blue Tap, as required;

	 	 	 
	 	(c) 	
      obtaining all required consents of third
  parties;

	 	 	 
	 	(d) 	
      the availability of exceptions to all securities
      registration, prospectus delivery, offering memorandum delivery, and
      take-over bid circular requirements in respect of the Transaction under
      applicable United States and Canadian securities laws;

	 	 	 
	 	(e) 	
      LEXG and its advisors having had a reasonable opportunity
      to review the foregoing financial statements (including corporate tax
      returns, bank account statements, general ledger listings, adjusting
      entries and opening trail balances) of Blue Tap, and that both LEXG and
      its accountant are satisfied with the content of such financial
      statements;

	 	 	 
	 	(f) 	
      no adverse material change in the business or financial
      condition of LEXG ;

	 	 	 
	 	(g) 	
      no adverse material change in the status or condition of
      Blue Tap’s assets:

	 	 	 
	 	(h) 	
      no adverse material change in the status or condition in
      the business or financial condition of Blue Tap since the execution of the
      Transaction Agreement;

	 	 	 
	 	(i) 	
      LEXG being provided with a list of all rights, lease
      agreements, surface agreements, approvals, and other associated of
      required permissions for the facility to be returned to operation, along
      with supporting documentation that Blue Tap has full ownership and or
      control of these;

	 	 	 
	 	(j) 	
      Blue Tap providing detailed schedule of all Freehold
      Lessor Royalty Encumbrances that may apply;

	 	 	 
	 	(k) 	
      Blue Tap to provide documentation that existing GORR to
      Advantage Oil & Gas applies only to Production or has been removed
      from the associated rights;

	 	 	 
	 	(l) 	
      Blue Tap to outline its plans and expectations for
      ongoing management and operation of the company and facilities during the
      completion of the Transaction for LEXG approval; and

	 	 	 
	 	(m) 	
      All parties at cooperate fully with each other’s due
      diligence, activities to expedite a full Transaction Agreement including
      purchasers right to access all facilities and sites pertaining to the
      assets.

2. Definitive Agreement

The parties shall negotiate the definitive terms of the
Transaction Agreement, acting reasonably and in good faith, with a view to
executing the agreement on or before September 1, 2013, whereafter this letter
agreement shall terminate and be no further force or effect.

3. Standstill

Until this letter agreement is either superseded by the
Transaction Agreement or terminated pursuant to section 2, Blue Tap agrees that
it will, for a period ending 11:59PM PST - September 1, 2013:

	 	(a) 	
      not solicit offers or have discussion with any third
      parties regarding its sale of its shares or assets or any other form of
      business combination or divestiture; and

	 	 	 
	 	(b) 	
      conduct its business only in, and not take any action
      except in, the usual, ordinary and regular course of business consistent
      with past practice.

4. Non Completion

In the event that the Transaction cannot be completed as a
result of any failure or breach by LEXG, LEXG agrees to pay Blue Tap an amount
of $25,000.00 CDN in consideration of its efforts.

5. Transaction Costs

In the event that this Transaction does not close, each of the
parties will be responsible for all costs (including, but limited to, financial
advisory, accounting, legal and other professional or consulting fees and
expenses) incurred by it in connection with the transactions contemplated
hereby.

6. Publicity

Blue Tap acknowledges that, as a reporting issuer, LEXG will be
required to give public disclosure about the Transaction and Blue Tap consents
to any such disclosure as reasonably required to satisfy LEXGs reporting
requirements with the SEC. LEXG agrees to provide Blue Tap with a draft of any
proposed public disclosure regarding the Transaction for its review and input at
least 18 hours prior to dissemination of such public disclosure.

7. Confidentiality Agreements

Each party will agree to keep the existence and the terms of
this letter of Intent confidential and will not make any disclosure except where
disclosure is required by law. In addition, each party agrees that any
information provided to the other in connection the negotiation and entering
into the definitive agreements for the Transaction will be maintained in
confidence, will not be disclose to any other party, other than each party’s
respective professional advisors, except where disclosure is compelled by
applicable law and will not be used by the party for any other purpose other
than the evaluation and completion of the Transaction. Each party will ensure
that its respective officers, directors, employees and consultants will agree to
maintain all information in connection with this Letter of Intent and the business combination transactions confidential. All obligations
regarding confidentiality will survive termination of this Letter of Intent.

8. General

This letter will be governed by and construed in accordance
with the laws of the State of Nevada. LEXG and Blue Tap submit to the
jurisdiction of the State of Nevada with the respect to any matters arising out
of this letter.

If you are in agreement with the foregoing, please confirm that
this letter accurately sets forth your understanding of the terms of the
proposed Transaction and the other matters set forth herein, by signing a copy
of this letter below and returning it to us prior to 12:00 p.m. (Vancouver time)
on June 11, 2013, failing which this letter shall be null and void.

This letter may be executed in any number of counterparts, each
of when executed and delivered (including by way of facsimile) is an original
but all of which taken together shall constitute one and the same
instrument.

We look forward to working together.

Yours very truly, 

LITHIUM EXPLORATION GROUP INC.

	By: 	  
	  	Alexander Walsh 
	Its: 	Chief Executive Officer 

Agreed and confirmed this 11th day of June, 2013

BLUE TAP RESOURCES

	By: 	/s/Vincent Murphy
	  	Vincent Murphy 
	Its: 	Director and Authorized Signatory

SCHEDULE “A”

This is Schedule “A” attached to and forming part of a Letter
of Intent, dated June 10, 2013 between Lithium Exploration Group Inc. and Blue
Tap Resources.

AREA:           
MORINVILLE, ALBERTA

	
LANDS & RIGHTS
      
DESCRIPTION 	VENDOR’S 
WORKING
      
INTEREST 	
TITLE DOCUMENTS 
	
ENCUMBRANCES 

	Township 55 Range 24 W4M Section 27, as to Petroleum and
      Natural Gas Rights from the surface down to the basement formation. 	100% 	Seventeen (17) Freehold Mineral Leases 	Freehold Lessor Royalty 3% GORR to Advantage
      Oil & Gas Ltd. 

	WELLS: 	  
	 	 
	00/16-27-055-24-W4M/00 	Standing well 
	 	 
	00/13-27-055-24-W4M/00 	Standing well 
	 	 
	00/14-27-055-24-W4M/00 	Disposal well 

Facilities and Pipelines

14-27-055-24-W4M disposal facilities, tanks, well site
equipment

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00218-of-00352.parquet"}]]